Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the purpose of targeting peripheral t-cell lymphoma (PTCL)

Tags: ASH Conference CoverageLymphoma (includes NHL, HL, CNS Lymphoma)

Published: 14 December 2019

Recent Videos: Lymphoma (includes NHL, HL, CNS Lymphoma)

video

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...

video

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...

video

Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, considers whether minimal residual disease (MRD) ...

video

Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, considers the ideal patient profile for ...

video

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma

Dr. Yasenchak, Medical Oncologist, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the ...

video

Ryan Lynch, MD, tells us about the four-year update on the outcomes of the MURANO study

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, tells us about the four-year update ...

video

Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, considers the ideal patient ...

video

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, on the benefits of zanubrutinib as compared ...

video

Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL

Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, offers impressions of the TRANSCEND-CLL-004 data presented ...

video

Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019

Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the three-year survival analysis of the ...

Related Videos

video-image

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

video-image

Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma

video-image

Ryan Lynch, MD, tells us about the four-year update on the outcomes of the MURANO study

video-image

Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

video-image

Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL

video-image

Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019

video-image

Andre Goy, MD, regarding the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy MCL

video-image

Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinib

video-image

Christopher Yasenchak, MD, on 1st line brentuximab vedotin + nivolumab in Hodgkin’s lymphoma

video-image

David Andorsky, MD, provides examples of how RWE has impacted the oncology community

video-image

Christopher Yasenchak, MD, tells us about the patient profile most suited for zanubrutinib in MCL

video-image

David Andorsky, MD, on the results of his RWE study investigating idelalisib in follicular lymphoma

video-image

Constantine Tam, MBBS, MD, compares the benefits of zanubrutinib to other BTK inhibitors

video-image

Sattva Neelapu, MD, tells us about the results of the ZUMA-1 study in DLBCL presented at ASH 2019

video-image

Sattva Neelapu, MD, on the role of CAR NK cell therapy in the treatment of B-cell malignancies

video-image

John Burke, MD, regarding tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in DLBCL

video-image

John Burke, MD, outlines the patient profile best suited for zanubrutinib in relapsed/refractory MCL

video-image

Jasmine Zain, MD, shares outcomes from the PRIMO study investigating duvelisib in PTCL

video-image

Jasmine Zain, MD, tells us about the novel approaches in development for the treatment of PTCL

video-image

Jasmine Zain, MD, discusses the most impressive studies in PTCL presented at ASH 2019

video-image

Jasmine Zain, MD, considers how peripheral T-cell lymphoma therapy has evolved in recent years

video-image

Michael Wang, MD, speculates on therapies for front-line and relapsed mantle cell lymphoma

video-image

Michael Wang, MD, on the distinct advantages of zanubrutinib in the management of lymphoma

video-image

Catherine Diefenbach, MD, explains how combination therapies are evolving in follicular lymphoma

video-image

Saro Armenian, DO, MPH, considers the relevance of bone marrow transplant in leukemia & lymphoma

video-image

Catherine Diefenbach, MD, regarding the unmet needs in the management of follicular lymphoma

video-image

Michael Wang, MD, shares details from the ZUMA-2 trial in mantle cell lymphoma presented at ASH 2019

video-image

Catherine Diefenbach, MD, on the recent data investigating obinutuzumab in follicular lymphoma

video-image

Michael Jain, MD, discusses how population-based outcomes in B-cell lymphomas are changing

video-image

Michael Jain, MD, offers perspective on the latest treatment trends for aggressive lymphomas

video-image

Michael Jain, MD, regarding CAR-natural killer (NK) cell therapy

video-image

Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma

video-image

Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma

video-image

Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma

video-image

Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas

video-image

Leslie Popplewell, MD, on the role of CAR-T cell therapy in aggressive B-cell lymphomas

video-image

Leslie Popplewell, MD, considers the use of CAR-T cell therapies in aggressive B-cell lymphomas

video-image

Leslie Popplewell, MD, offers opinion on the next frontier in the development of CAR-T treatment

video-image

Paul M. Barr, MD, considers the role of CAR-T therapy in B-cell lymphomas

video-image

Andre Goy, MD, explains how lenalidomide will impact the management of FL and MZL

video-image

Andre Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Andre Goy, MD, shares the most exciting advances in lymphoma coming out of ASCO 2019

video-image

Andrew Goy, MD, explains how the approval of lenalidomide will impact the management of FL & MZL

video-image

Andrew Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Andrew Goy, MD, elaborates on the most exciting recent clinical advances in lymphoma

video-image

Lori A. Leslie, MD, on the recent data regarding umbralisib in relapsed/refractory lymphoma

video-image

Lori A. Leslie, MD, speculates on how CAR-T cell therapy may be combined to treat lymphomas

video-image

Lori A. Leslie, MD, on how CAR-T cell therapy has impacted the treatment of B-cell lymphomas

video-image

Jasmine Zain, MD, on the most exciting studies in lymphoma presented at ASH 2018

video-image

Jasmine Zain, MD, considers the impact of the new induction regimen in PTCL

video-image

Jasmine Zain, MD, defines successful induction regimens when treating PTCL

video-image

Jasmine Zain, MD, elaborates on the investigation of novel induction regimens in PTCL

video-image

Jasmine Zain, MD, regarding the standard of care in treatment of PTCL

video-image

Sattva Neelapu, MD, speculates on the future of CAR-T therapies in lymphoma

video-image

Sattva Neelapu, MD, considers the use of axicabtagene ciloleucel with elderly lymphoma patients

video-image

Sattva Neelapu, MD, on real-world experience & clinical studies examining axicabtagene ciloleucel

video-image

Sattva Neelapu, MD, regarding the ZUMA-1 two-year follow-up study in DLBCL

video-image

Edward Copelan, MD, considers the role of allogeneic transplantation in lymphoma & multiple myeloma

video-image

Andrew Pecora, MD, shares his thoughts on the necessity of allogeneic transplants to MML patients

video-image

Elizabeth Budde, MD, evaluates the clinical study investigating mosunetuzumab from ASH 2018

video-image

Elizabeth Budde, MD, discusses the role of CAR-T therapies in lymphoma treatment algorithms

video-image

Robert Rifkin, MD, shares his thoughts on if a rituximab biosimilar can replace rituximab

video-image

Jeff Sharman, MD, shares his thoughts on rituximab biosimilars in follicular lymphoma

video-image

Lorenz Trumper, MD, discusses the results of ECHELON-2 in frontline PTCL

video-image

Lorenz Trumper, MD, on the current standard of care for the frontline treatment of PTCL

video-image

Lorenz Trumper, MD, speaks on the differences between B-Cell and T-Cell lymphomas

video-image

Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL

video-image

Swaminathan P. Iyer, MD, shares exciting studies regarding the treatment of PTCL from ASH 2018

video-image

Swaminathan P. Iyer, MD, on the outcomes of the ECHELON-2 study in PTCL

video-image

Andre Goy, MD, comments on the long-term outcome of acalabrutinib in MCL

video-image

Andre Goy, MD, discusses his real-world experience using axi-cel CAR-T cell therapy

video-image

Andre Goy, MD, on research regarding the use of axi-cel CAR-T cell therapy in DLBCL

video-image

Tatyana Feldman, MD, regarding improvements in the treatment of CTCL

video-image

Tatyana Feldman, MD, on exciting studies from ASH 2018 regarding the treatment of PTCL

video-image

Frederick Locke, MD, on the management of toxicity withs with CAR-T therapies

video-image

Julie Vose, MD, discusses improvements made in the delivery of CAR-T therapies in lymphoma

video-image

Frederick Locke, MD, discusses how to integrate CAR-T with stem cell transplant

video-image

Andre Goy, MD, on responses & outcomes when treating lymphoma with CAR-T therapies

video-image

Tatyana Feldman, MD, shares outcomes of the ECHELON-2 study in PTCL

video-image

Tatyana Feldman, MD, offers opinion on the ECHELON-2 study in PTCL

video-image

Frederick Locke, MD, on the use of CAR-T therapies in leukemia and lymphoma

video-image

Tatyana Feldman, MD, on unmet needs in peripheral T-cell lymphoma (PTCL)

video-image

Julie Vose, MD, on if CAR-T therapies are showing impressive results in lymphoma

video-image

Andrew Pecora, MD, tells us about the results of the CPIT trial presented here at ASH

video-image

Julie Vose, MD, tells us about the results of the AUGMENT study in relapsed/refractory indolent NHL

video-image

Julie Vose, MD, discusses whether polatuzumab improves outcomes in DLBCL patients

video-image

Andre Goy, MD, discusses how CAR-T therapies are being integrated into the treatment of large B-Cell lymphoma

video-image

Swaminathan Padmanabhan Iyer, MD, on if ECHELON-2 study is game changing for patients with PTCL

video-image

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

video-image

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

video-image

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

video-image

Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL

video-image

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

video-image

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

video-image

Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma

video-image

John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL

video-image

Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types

video-image

Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment

video-image

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

video-image

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

video-image

John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies

video-image

John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma

video-image

Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma

video-image

Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing

video-image

David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies

video-image

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

video-image

Jane N. Winter, MD, discusses how CAR T-Cell therapies will impact the treatment of lymphomas

video-image

Jane N. Winter, MD, shares the clinical evidence supporting brentuximab vedotin in older patients

video-image

Jane N. Winter, MD, on whether checkpoint inhibitors can be used effectively in Hodgkin’s Lymphoma

video-image

Jane N. Winter, MD, explains how PD-1 and PD-L1 expression changes the way DLBCL is treated

video-image

Andre Goy, MD, tells us about the long-term outcomes of the ZUMA-1 trial

video-image

Andre Goy, MD tells us about the BTK combination with lenalidomide in MCL

video-image

Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL

video-image

John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma

video-image

John Gerecitano, MD, on what genetic predictors of response we have for follicular lymphoma

video-image

John Gerecitano, MD, discusses how PET staging affects outcomes and prognosis of follicular lymphoma

video-image

John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma

video-image

Miles Prince, MD, discusses I-O compounds and T-Cell Lymphoma treatment algorithms

video-image

Miles Prince, MD, on which emerging compounds for T-Cell Lymphomas look promising

video-image

Miles Prince, MD, discusses the efficacy and safety of brentuximab vedotin to treat CTCL patients

video-image

Miles Prince, MD, on the role CD30 plays when selecting a treatment algorithm for CTCL patients

video-image

Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients

video-image

Sattva Neelapu, MD, on novel agents and up-front approaches showing efficacy in lymphomas

video-image

Sattva Neelapu, MD, discusses efficacy results of the ZUMA-1 trial

video-image

John P. Leonard, MD, on CAR-T cell therapies being developed for the treatment of lymphomas

video-image

John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms

video-image

John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas

video-image

Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin Lymphoma

video-image

Sattva Neelapu, MD shares safety results of the ZUMA-1 trial in patients with NHL

video-image

Matthew Davids, MD discusses his study using ibrutinib plus FCR in younger CLL patients

video-image

John P. Leonard, MD discusses improving outcomes in high risk follicular lymphoma patients

video-image

Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL

video-image

Kathryn Kolibaba, MD, lists key takeaways from the lymphoma oral session at ASCO 2017

video-image

Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO

video-image

Kathryn Kolibaba, MD, describes the results of the BRIGHT study in front-line indolent NHL patients

video-image

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

video-image

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

video-image

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

video-image

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

video-image

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

video-image

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

video-image

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

video-image

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

video-image

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

video-image

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

video-image

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

video-image

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

video-image

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

video-image

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

video-image

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

video-image

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

video-image

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

video-image

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Advances In B-Cell Lymphoma From ASH 2015

video-image

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

video-image

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

video-image

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

video-image

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

video-image

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

video-image

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

video-image

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

video-image

Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data

video-image

Angela Dispenzieri, MD, speculates on the the clinical impact of the TOURMALINE-AL1 study

video-image

Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL

video-image

Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study

video-image

Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019

video-image

Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019

video-image

Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies

video-image

Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL

video-image

Daniel Pollyea, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019

video-image

Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients

video-image

Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019

video-image

Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML

video-image

Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality

video-image

Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes

video-image

Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms

video-image

Jae H. Park, MD, on the factors associated with improved survival after CD19 CAR-T cell therapy

video-image

Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients

video-image

Chaitra Ujjani, MD, tells us about the results of the Phase 3 ELEVATE TN study in CLL

video-image

Angela Dispenzieri, MD, expands on the side effects from the TOURMALINE-AL1 study

video-image

Amrita Krishnan, MD, elaborates on BCMA-directed strategies for multiple myeloma patients

video-image

Chaitra Ujjani, MD, offers her impression of the Phase 2 CAPTIVATE study in CLL

video-image

Amrita Krishnan, MD, tells us about the Phase 3 Dreamm-3 study presented at ASH 2019

video-image

David Andorsky, MD, defines RWE and explains how it compliments clinical trial results

video-image

Amrita Krishnan, MD, tells us about the outcomes of the CARTITUDE-1 study presented at ASH 2019

video-image

David Andorsky, MD, discusses the implications of real-world evidence for oncologists

video-image

Amrita Krishnan, MD, tells us about the results of the Phase 1 study investigating CC-93269 in MM

video-image

James Essell, MD, offers opinion on the future of off-the-shelf CAR-T cell therapy

video-image

Amer Zeidan, MBBS, considers RWE in older patients with acute myeloid malignancies

video-image

James Essell, MD, regarding off-the-shelf CAR NK cell therapy in treating B-cell malignancies

video-image

Amer Zeidan, MBBS, speculates on the role of immune checkpoint blockades in myeloid malignancies

video-image

James Essell, MD, offers his impression the data investigating the bi-specific CAR-T cell therapy

video-image

Amer Zeidan, MBBS, elaborates on the role of venetoclax in treatment of MDS

video-image

James Essell, MD, discusses the integration of stem cell transplantation in the treatment of myeloma

video-image

Amer Zeidan, MBBS, on the role of oral therapies in the treatment of myeloid malignancies

video-image

Constantine Tam, MBBS, MD, considers the role of CAR-T cell therapy in chronic lymphocytic leukemia

video-image

Peter M. Voorhees, MD, explains how daratumumab is changing the way MM patients are treated today

video-image

Constantine Tam, MBBS, MD, tells us about the Phase 2 CAPTIVATE study presented at ASH 2019

video-image

Peter M. Voorhees, MD, summarizes the outcomes of the Phase 2 Griffin study in newly diagnosed MM

video-image

Shyamala Navada, MD, MSCR, discusses the treatment of elderly patients with myeloid malignancies

video-image

Constantine Tam, MBBS, MD, regarding the data that lead to the recent FDA approval of zanubrutinib

video-image

Shyamala Navada, MD, MSCR, offers opinion on how the treatment landscape of MDS is evolving

video-image

Sattva Neelapu, MD, considers whether off-the-shelf CAR-T cell therapy is becoming a reality

video-image

Constantine Tam, MBBS, MD, offers his impression of the Phase 2 CAPTIVATE study in CLL from ASH '19

video-image

Shyamala Navada, MD, MSCR, on how oral therapies will impact the treatment of myeloid malignancies

video-image

John Burke, MD, offers opinion on how physicians should be thinking about the use of BTK inhibitors

video-image

Robert Rifkin, MD, FACP, on whether medical oncologists are embracing therapeutic biosimilars

video-image

Robert Rifkin, MD, FACP, on the role of daratumumab as maintenance therapy in the management of MM

video-image

Luciano J. Costa, MD, PhD, offers opinion on whether MRD tests can help guide treatment decisions

video-image

Robert Rifkin, MD, FACP, offers opinion on the most promising studies in MM presented at ASH 2019

video-image

Luciano J. Costa, MD, PhD, explains how academic and community oncologists can utilize MRD tests

video-image

Courtney DiNardo, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Courtney DiNardo, MD, describes the targeted therapy landscape in acute myeloid leukemia

video-image

Courtney DiNardo, MD, regarding the evolution of treatment in acute myeloid leukemia

video-image

Courtney DiNardo, MD, considers the role of intensive chemotherapy in newly diagnosed AML

video-image

Max Topp, MD, on whether a risk management plan exists to help reduce toxicity of CAR-T cell therapy

video-image

Bruce Feinberg, DO, elaborates on how oncologists are utilizing real-world evidence today

video-image

John Seymour, MBBS, PHD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Bruce Feinberg, DO, provides examples of how RWE has impacted decision-making in oncology

video-image

John Seymour, MBBS, PHD, elaborates on the updated data from the Phase 3 MURANO trial

video-image

Bruce Feinberg, DO, defines and explains the role of real-world evidence

video-image

Kylee Martens, MD, compares rasburicase versus allopurinol in patients with hyperuricemia

video-image

Michael Wang, MD, regarding the pivotal clinical data that lead to the FDA approval of zanubrutinib

video-image

Kylee Martens, MD, on the role of rasburicase in managing TLS in patients with renal dysfunction

video-image

Kylee Martens, MD, on those patient types more suited for treatment with rasburicase vs. allopurinol

video-image

Max Topp, MD, shares the long-term results of the ZUMA-1 trial presented at ASH 2019

video-image

Kylee Martens, MD, considers whether there are certain patient types more prone to TLS

video-image

Luciano J. Costa, MD, PhD, on whether minimal residual disease can be used to predict outcomes

video-image

Robert Rifkin, MD, FACP, tells us about the outcomes of the LYRA study presented at ASH 2019

video-image

Luciano J. Costa, MD, PhD, on how measurement of MRD is evolving as an endpoint in clinical trials

video-image

Joseph Alvarnas, MD, on seeking creative solutions to provide proper access to innovative therapy

video-image

Saro Armenian, DO, MPH, reflects on promising clinical innovations in the management of leukemia

video-image

Joseph Alvarnas, MD, on the challenges facing cancer centers when delivering innovative therapies

video-image

Saro Armenian, DO, MPH, on bone marrow transplant survivorship outcomes in AML patients

video-image

Joseph Alvarnas, MD, regarding CAR-T cell therapy in an era of value-based care

video-image

Andrew Cowan, MD, elaborates on the role of isatuximab in the management of multiple myeloma

video-image

Joseph Alvarnas, MD, on how to responsibly integrate clinical innovations into treatment algorithms

video-image

Michael Jain, MD, offers his opinion on off-the-shelf CAR-T cell therapy

video-image

James McCloskey, MD, regarding the QUASAR-001 study presented at ASH 2019

video-image

Michael Jain, MD, shares the outcomes of the US CAR-T Cell Consortium study from ASH 2019

video-image

Andrew Cowan, MD, on the most promising clinical data in multiple myeloma presented at ASH 2019

video-image

James McCloskey, MD, considers how the role of molecular profiling in AML is changing

video-image

Andrew Cowan, MD, provides an overview of the use of CAR-T cell therapy in multiple myeloma

video-image

James McCloskey, MD, speculates on the landscape of MDS as a result of data presented at ASH '19

video-image

James McCloskey, MD, shares his impression of the Phase 3 ASCERTAIN trial in MDS

video-image

Andrew Cowan, MD, discusses the role of human BCMA CAR-T cells in the management of multiple myeloma

video-image

John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms

video-image

John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms

video-image

Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL

video-image

John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms

video-image

Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas

video-image

Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition

video-image

John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis

video-image

Joshua Richter, MD, discusses the data investigating iberdomide presented at ASH 2019

video-image

Joshua Richter, MD, provides opinion on the role of BCMA CAR-T cells in the management of MM

video-image

Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019

video-image

Joshua Richter, MD, regarding the Phase 3 CANDOR study in relapsed/refractory multiple myeloma

video-image

Parameswaran Hari, MD, MRCP, on novel combination treatment options & sequencing strategies in MM

video-image

Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma

video-image

Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies

video-image

Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia

video-image

Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML

video-image

Catherine Smith, MD, on whether all acute myeloid leukemia patients should be tested for FLT3

video-image

Leslie Popplewell, MD, considers whether there is sufficient evidence supporting bridging therapy

video-image

Deepu Madduri, MD, on how CAR-T cell therapy plays a role in the management of multiple myeloma

video-image

Catherine Smith, MD, tells us about the outcomes of the Phase 3 ADMIRAL trial presented at ASH 2019

video-image

Deepu Madduri, MD, elaborates on the outcomes of the CARTITUDE-1 study

video-image

Carol Moreno, MD, PhD, on the Phase 3 trial examining ibrutinib + rituximab versus FCR in CLL

video-image

Carol Moreno, MD, PhD, on how the outcomes of the illUMINTATE trial impact treatment of CLL

video-image

Yana Pikman, MD, regarding research outcomes from the LEAP Consortium

video-image

Jasmine Zain, MD, discusses novel treatment research regarding transplants at City of Hope

video-image

Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia

video-image

Rod A. Humerickhouse, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Rod A. Humerickhouse, MD, PhD, considers testing for minimal residual disease in CLL

video-image

Rod A. Humerickhouse, MD, PhD, on MRD as a surrogate marker in chronic lymphocytic leukemia

video-image

Jason Butler, PhD, considers how vascular integrity impacts the leukemia-initiating metabolic switch

video-image

Rena Feinman, PhD, considers the the role of the microbiome in cancer & response to therapy

video-image

Jason Butler, PhD, on how age-associated aberrant MAPK signaling impacts hematopoiesis

video-image

Rod A. Humerickhouse, MD, PhD, regarding potential side effects from venetoclax + rituximab in CLL

video-image

Sen Zhuang, MD, PhD, shares the research & development philosophy at Janssen

video-image

Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab

video-image

Sen Zhuang, MD, PhD, shares details from the LCAR-838M study in relapsed/refractory MM

video-image

Sen Zhuang, MD, PhD, speculates on how LCAR-838M may impact the treatment of MM

video-image

Sen Zhuang, MD, PhD, regarding the development of LCAR-B38M

video-image

Rod A. Humerickhouse, MD, PhD, elaborates on venetoclax in treatment of MM

video-image

Katja Weisel, MD, provides opinion on anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Habte Yimer, MD, considers the outcomes of the GRIFFIN study in multiple myeloma

video-image

Katja Weisel, MD, discusses current maintenance regimens in multiple myeloma

video-image

Habte Yimer, MD, speculates on the future of anti-BCMA CAR-T cell therapy

video-image

Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients

video-image

Katja Weisel, MD, elaborates on the outcomes of the TOURMALINE-MM3 study

video-image

Habte Yimer, MD, regarding the POLLUX and CASTOR studies presented at ASH 2018

video-image

Keith Pratz, MD, on genetic testing in AML prior to the start of therapy

video-image

Katja Weisel, MD, shares outcomes of the POLLUX and CASTOR studies from ASH 2018

video-image

Habte Yimer, MD, regarding the Lyra trial in newly diagnosed multiple myeloma presented at ASH 2018

video-image

Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today

video-image

Peter Vorhees, MD, discusses the outcomes of the TOURMALINE-MM3 study in MM

video-image

Peter Vorhees, MD, discusses outcomes of the ALCYONE trial in multiple myeloma patients

video-image

Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL

video-image

Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Keith Pratz, MD, comments on the Phase I study of gilteritinib presented at ASH 2018

video-image

Carol Moreno, MD, PhD, shares outcomes from the iLLUMINATE trial presented at ASH 2018

video-image

Keith Pratz, MD, regarding the reliability of the companion diagnostic test for FLT3

video-image

Keith Pratz, MD, describes how gilteritinib fits into treatment algorithms for AML

video-image

James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML

video-image

Rafael Fonseca, MD, on the effectiveness of anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

James McCloskey, MD, regarding molecular testing in acute myelogenous leukemia

video-image

Rafael Fonseca, MD, discusses maintenance regimens for multiple myeloma

video-image

James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients

video-image

Rafael Fonseca, MD, regarding the TOURMALINE-MM3 study in multiple myeloma

video-image

James McCloskey, MD, describes how the FLT3 mutation influences treatment decisions in AML

video-image

Rafael Fonseca, MD, elaborates on the outcomes of the POLLUX and CASTOR studies in MM

video-image

James McCloskey, MD, speculates on the reliability of the companion diagnostic test for FLT3

video-image

Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patterns

video-image

Edward Copelan, MD, regarding gilteritinib for patients with FLT3+ AML

video-image

Nikhil Munshi, MD, discusses the outcomes of the TOURMALINE-MM3 study in multiple myeloma

video-image

Nikhil Munshi, MD, discusses the POLLUX and CASTOR studies regarding the use of daratumumab in MM

video-image

Nikhil Munshi, MD, regarding the outcomes of the CA204-142 study from ASH 2018

video-image

Nikhil Munshi, MD, considers how ID2 function impacts oncogenesis in multiple myeloma

video-image

Nizar Bahlis, MD, speculates on the future of anti-BCMA CAR-T cell therapy in MM

video-image

Nizar Bahlis, MD, describes current maintenance regimens for multiple myeloma

video-image

John Burke, MD, elaborates on the Beat AML umbrella study

video-image

Nizar Bahlis, MD, discusses the outcomes of the TOURMALINE-MM3 study from ASH 2018

video-image

John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML

video-image

Nizar Bahlis, MD, regarding the impact of the POLLUX and CASTOR studies from ASH 2018

video-image

John Burke, MD, elaborates on the incorporation of venetoclax into AML treatment regimens

video-image

John Burke, MD, speaks to the reliability of the FLT3 mutation test

video-image

Elizabeth Budde, MD, on how City of Hope has overcome logistical hurdles associated with CAR-T

video-image

John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment

video-image

Robert Rifkin, MD, discusses the rationale for genetically profiling AML patients

video-image

Robert Rifkin, MD, explains whether or not anti-BCMA CAR-T cell therapy looks promising

video-image

Robert Rifkin, MD, discusses the outcomes of the TOURMALINE-MM3 study

video-image

Robert Rifkin, MD, talks about what clinical data could change the way multiple myeloma is treated

video-image

Ravi Vij, MD, on molecular testing and acute myelogenous leukemia

video-image

Samer Khaled, MD, tells us about the MEDALIST study examining myelodysplastic syndrome

video-image

Ravi Vij, MD, considers anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Ravi Vij, MD, discusses current maintenance regimens for multiple myeloma

video-image

Samer Khaled, MD, on incorporating venetoclax into treatment regimens for AML

video-image

Ravi Vij, MD, shares details regarding his clinical study presented at ASH 2018

video-image

Samer Khaled, MD, regarding gilteritinib in treatment of acute myelogenous leukemia

video-image

Samer Khaled, MD, shares details of his study examining the use of CAR-T therapy in ALL

video-image

Ravi Vij, MD, regarding the POLLUX and CASTOR clinical studies in multiple myeloma

video-image

Andrzej Jakubowiak, MD, shares thoughts on the POLLUX and CASTOR clinical studies

video-image

Andrzej Jakubowiak, MD, PhD, discusses maintenance regimens in treatment of multiple myeloma

video-image

Andrzej Jakubowiak, MD, PhD, regarding the ALCYONE trial presented at ASH 2018

video-image

Andrzej Jakubowiak, MD, discusses the outcomes of the GRIFFIN study from ASH 2018

video-image

Chadi Nabhan, MD, MBA, on the role of advanced practice practitioners

video-image

Chadi Nabhan, MD, MBA, shares what is being done to prevent oncologist burnout

video-image

Chadi Nabhan, MD, MBA, discusses the key factors contributing to physician burnout

video-image

Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements

video-image

Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA

video-image

Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM

video-image

Sundar Jagannath, MD, regarding proteasome inhibitors in the treatment of MM

video-image

Maria-Victoria Mateos, MD, elaborates on the TOURMALINE-MM3 presented at ASH 2018

video-image

Maria-Victoria Mateos, MD, on the addition of daratumumab to revlimid/dexamethasone in MM

video-image

Sundar Jagannath, MD, considers maintenance regimens for multiple myeloma (MM) patients

video-image

Sundar Jagannath, MD, elaborates on the outcomes of CA204-142 in MM

video-image

Maria-Victoria Mateos, MD, regarding the CASTOR trial presented at ASH 2018

video-image

Maria-Victoria Mateos, MD, shares outcomes from the ALCYONE study in MM

video-image

Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax

video-image

Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in younger CLL patients

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients

video-image

Andre Goy, MD, on immunotherapy and the treatment of hematologic malignancies

video-image

Andre Goy, MD, considers checkpoint inhibitors in hematologic malignancies

video-image

Frederick Locke, MD, on whether CAR-T therapies will be expanded into solid tumors

video-image

Julie Vose, MD, on management of common toxicities with CAR-T therapies

video-image

David Siegel, MD, explains the results of MM014 study presented at ASH

video-image

Frederick Locke, MD, on what improvements to turn around time with CAR-T therapies

video-image

David Siegel, MD, discusses anti-BCMA CAR-T cell therapy for multiple myeloma patients

video-image

David Siegel, MD, talks about the TOURMALINE-MM3 study and the treatment of multiple myeloma

video-image

David Siegel, MD, shares his thoughts on the daratumamab studies presented at ASH 2018

video-image

Ravi Vij, MD, on the outcomes of the TOURMALINE-MM3 study in multiple myeloma

video-image

Keith Pratz, MD, discusses venetoclax in treatment of acute myeloid leukemia (AML)

video-image

James McClosky, MD, on using newly FDA approved gilteritinib for patients with AML

video-image

Peter Vorhees, MD, discusses the outcomes of the GRIFFIN trial in multiple myeloma

video-image

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

video-image

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

video-image

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital

video-image

Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients

video-image

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

video-image

Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations

video-image

Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN

video-image

Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study

video-image

Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study

video-image

Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy

video-image

Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy

video-image

James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations

video-image

James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy

video-image

Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib

video-image

Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML

video-image

Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia

video-image

Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML

video-image

James R. Downing, MD, discusses the significant studies presented at ASH 2017

video-image

James R. Downing, MD, on the evolution of St. Jude Children’s Research Hospital

video-image

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

video-image

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

video-image

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

video-image

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

video-image

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

video-image

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

video-image

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

video-image

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

video-image

Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM

video-image

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

video-image

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

video-image

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

video-image

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

video-image

Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy

video-image

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

video-image

Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses

video-image

Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM

video-image

Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease

video-image

Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis

video-image

Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017

video-image

Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients

video-image

Parameswaran Hari, MD, MRCP, MS, on checkpoint inhibitors and MM treatment algorithms

video-image

David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD

video-image

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

video-image

Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients

video-image

Michael Boxer, MD, considers broader uses for fostamatinib

video-image

Paul Richardson, MD, on the importance of real world evidence (RWE)

video-image

Paul Richardson, MD, shares the efficacy outcomes of GSK-916 in relapsed/refractory MM patients

video-image

Paul Richardson, MD, on adding CAR T-cell therapy to multiple myeloma treatment algorithms

video-image

Robert Soiffer, MD, on other applications that IL-2 might have outside of treating chronic GVHD

video-image

Robert Soiffer, MD, on some of the innovative approaches to treating chronic GVHD

video-image

Robert Soiffer, MD, discusses current treatments available for chronic GVHD

video-image

Robert Soiffer, MD, explains GVHD and some of the complications that come along with it

video-image

Robert M. Rifkin, MD, on excluding transplantation from MM treatment algorithms

video-image

Robert M. Rifkin, MD, discusses if COMPASS is close to its goal of achieving whole genome sequencing

video-image

Robert M. Rifkin, MD, on the Connect Multiple Myeloma patient registry improving characterization

video-image

Robert M. Rifkin, MD, on how the Connect Multiple Myeloma patient registry is helping patients

video-image

David S. Siegel, MD, shares his thoughts on the most exciting clinical trial presented at ASH 2017

video-image

David S. Siegel, MD, discusses proteasome inhibitors and Multiple Myeloma

video-image

David S. Siegel, MD, discusses how stem cell transplant figures into MM treatment algorithms

video-image

David S. Siegel, MD, on how molecular profiling is helping drive treatment strategies

video-image

C. Ola Landgren, MD, discusses remaining major unmet medical needs for MM

video-image

C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM

video-image

C. Ola Landgren, MD, discusses continuous therapy vs fixed duration therapy in MM patients

video-image

C. Ola Landgren, MD, on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials

video-image

John Gerecitano, MD, talks about tazemetostat’s class and mechanism of action

video-image

Miles Prince, MD, on the challenges to recruit and accrue patients to rare-cancer clinical studies

video-image

Sattva Neelapu, MD, shares his approach to optimizing CAR T-Cell therapies

video-image

John P. Leonard, MD, on the role social media plays in medicine

video-image

Gary Gordon, MD, PhD, on MRD endpoint for outcomes in the MURANO study

video-image

Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial

video-image

Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial

video-image

Matthew Davids, MD, on how checkpoint inhibitors are being developed for hematologic malignancies

video-image

Sagar Lonial MD, FACP, on expectations for response in the challenging patient type

video-image

Sagar Lonial MD, FACP, on MM patients not responding to monotherapy and combination regimens

video-image

Sagar Lonial MD, FACP, discusses unmet need for multiple myeloma patients

video-image

Sagar Lonial MD, FACP, on predicting venetoclax sensitivity in MM using biologic active assays

video-image

Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax

video-image

Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients

video-image

Sattva Neelapu, MD shares his advice for sites that are new to treating with CAR T-Cell therapies

video-image

Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study

video-image

Sagar Lonial MD, FACP tells us about the immunomodulatory mechanism of action of daratumumab

video-image

Sagar Lonial MD, FACP on whether relapsed multiple myeloma patients should be profiled molecularly

video-image

Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL

video-image

John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL

video-image

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

video-image

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

video-image

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

video-image

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

video-image

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

video-image

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

video-image

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

video-image

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

video-image

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

video-image

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

video-image

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

video-image

David Miklos, MD, on developing an orphan drug for a small population of patients

video-image

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

video-image

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

video-image

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

video-image

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

video-image

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

video-image

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

video-image

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

video-image

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

video-image

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

video-image

Alexander Perl, MD, discusses treatment options for AML patients

video-image

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

video-image

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

video-image

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

video-image

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

video-image

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

video-image

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

video-image

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

video-image

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

video-image

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

video-image

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

video-image

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

video-image

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

video-image

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

video-image

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

video-image

Michael Kauffman, MD, on how Selinexor works

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

video-image

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

video-image

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

video-image

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

video-image

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

video-image

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

video-image

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

video-image

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

video-image

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

video-image

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

video-image

Edward Copelan, MD, discusses the Levine Cancer Institute Program

video-image

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

video-image

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

video-image

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

video-image

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

video-image

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

video-image

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

video-image

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

video-image

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

video-image

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

video-image

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

video-image

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

video-image

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

video-image

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

video-image

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

video-image

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

video-image

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

video-image

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

video-image

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today

video-image

Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015

video-image

ASH 2015 Data Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab

video-image

Precision Medicine Coming to Bone Marrow Transplant

video-image

Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016

video-image

Real World Experience Idelalisib - Rituximab Combination for Relapsed CLL